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A novel human monocyte-derived neutrophil chemotactic factor(MDNCF), which
is clearly distinct from either IL-1 or TNF, has been identified and purified from
LPS-stimulated human monocyte-conditioned media. MDNCF has been shown to
be a specific chemoattractant for neutrophils but not for monocytes (1, 2) . ThecDNA
forMDNCF has been cloned and the amino acid sequence of the protein has been
deduced (3) . The mature form ofMDNCF consists of 72 amino acids . An identical
and fully activeMDNCF has been chemically synthesized (4) and expressed in Esch-
erichia coli(R . Furuta, M . Yamada, andK . Matsushima, manuscript submitted for
publication) .
MDNCF has the capability to chemoattract neutrophils and also stimulate de-
granulation and respiratory burst response, resulting in release oflysosomalenzymes
and generation of superoxide anion and hydrogen peroxide (5, 6) . The directional
migration of neutrophils in response to very low concentrations ofMDNCF sug-
gests the presence of specific plasma membrane receptors on neutrophils through
which the activating peptide exerts its effects. The recent availability ofa large amount
of pure, active recombinant MDNCF has permitted us to examine whether poly-
morphonuclear neutrophils (PMN) express specific cell surface receptors forMDNCF
Materials and Methods
Reagents.
￿
Human rIL-la (2 x 10' U/mg) and TNFa (10' U/mg) were obtained from
Dainippon Pharmaceutical Company, Osaka, Japan . Recombinant human MDNCF (2 x
10 6 U/mg) has been expressed inE . coli and purified to homogeneity (R . Furuta, M . Yamada,
andK . Matsushima, manuscript submitted for publication) . C5a, LTB4, PAF, CHAPS, DSS,
and protease inhibitors were purchased from Sigma Chemical Co., St . Louis, MO.
Preparation ofHuman Neutrophils.
￿
Citrated peripheral venous blood was obtained from normal
human volunteers and a granulocyte-enriched fraction was obtained by leukapheresis from
the National Institutes of Health Clinical Center Transfusion Medicine Department, Bethesda,
MD. Neutrophils were purified as described by English and Andersen (7) . 95-98% of cells
were identified as PMN and 2-5% cells were mononuclear cells with Wright's stain . The
human promyelocytic cell line HL60 (8) was maintained and cultured in RPMI 1640 supple-
ment with 10% FCS .
Radiolabeling ofHuman MDNCF .
￿
To radiolabel human MDNCF, 20 l~g of pure recom-
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binant material in 50 Etl 0 .1 M borate buffer, pH 8.5, was added to 1 MCi 1251-labeled (2,200
Ci/mmol ; monoiodinated) Bolton Hunter reagent, incubated, and fractionated as described
(9) . The biological potency ofthe radiolabeled material was checked by assaying myeloperox-
idase release from neutrophils as described by Schroder et al . (5) .
Binding of 1251-MDNCF to Neutrophils.
￿
Binding of the labeled MDNCF to the intact
human neutrophils was carried out as previously described for IL-1 (9) . In standard binding
assays, 2 x 10 6 cells were incubated in duplicate with 4 ng 1251-MDNCF in RPMI 1640
medium with 10 mg/ml BSA in a total volume 200 pl . The nonspecific binding was carried
out by parallel incubation in the presence of 80-fold excess of unlabeled MDNCF.
Chemical Crosslinking andSDS-PAGE Analysis.
￿
For chemical crosslinking experiments, 10'
neutrophils suspended in 1 ml RPMI 1640 medium were incubated with 1251-MDNCF (20
ng) for 1 h at 4°C . Parallel experiments were performed in the presence ofunlabeledMDNCF
(2,000 ng) in a similar manner. After incubation, the cells were washed twice with 1 ml cold
D-PBS and were suspended in 100 plD-PBS. Then, disuccinimidyl suberate (DSS) at varying
concentrations in DMSO was added to give a final concentration of 0 .75, 1, and 1 .25 mg
DSS/ml . The mixtures were incubated for 1 h at 4°C . The cells were washed with cold D-PBS
twice and suspended in 50 it] D-PBS containing 9 mM CHAPS and 2 tl of the mixture,
each containing PMSF (12.8 ng), leupeptin (16 ng), pepstatin (80 ng), and chymostatin (2
ng) . The detergent extraction mixtures were incubated on ice for 5min and then centrifuged
at 10,000gfor 15 min at 4°C . SDS-PAGE was done as described by Laemmli (10), followed
by autoradiography .
Results and Discussion
Radiolabeling ofMDNCF .
￿
Carrier-free recombinant MDNCF was labeled with
Bolton Hunter reagent and chromatographed on a Sephadex column . The radiola-
beledMDNCFwashomogenousonSDS-PAGE and free ofuncoupled Bolton-Hunter
reagent (data not shown) . The biological activity of the radiolabeled MDNCF was
retained as assessed by the measurement of myeloperoxidase release from neutro-
phils (data not shown) . The specific activity of labeled MDNCF was estimated to
be 7 x 10' cpm/ug of protein .
Speck Binding of1251-MDNCF to Neutrophils.
￿
As shown in Fig . 1, excess amount
of nonradioactive MDNCF was able to inhibit the binding of 1251-MDNCF to neu-
trophils by >95% . This inhibitory effect of unlabeledMDNCF was dose dependent .
In contrast, other chemotactic cytokines and agents such as TNF, IL-la, FMLP,
LTB4, C5a, and platelet activating factor did not exert significant inhibitory effects
on binding of radiolabeled MDNCF to neutrophils, demonstrating specificity of
binding of 1251-MDNCF and establishing thatMDNCF receptors are distinct from
any other chemotactic cytokine or agent receptors .
FIGURE 1 . Competition for the binding of 1251-
MDNCF by unlabeled MDNCF, other cytokines, and
chemoattractant to human neutrophils . Human neutro-
phils were incubated at 4°C for 1 h with 4 ng I25l-
MDNCF as described in Materials and Methods, in the
presence of various amounts of unlabeled MDNCF,
TNF, IL-1, FMLP, C5a, LT4, and platelet activating
factor as indicated . The binding is expressed as a per-
centage of binding obtained with 1251-MDNCF alone .
The results represent three independent experiments .b er
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Kinetics of Bindingof125I-MDNCFto itsReceptor.
￿
Fig. 2 shows a representative ki-
netic profile ofthe binding of 1251-MDNCF to neutrophils at 4°C. The binding es-
sentially reached equilibrium by 1 h.
ScatchardAnalysis ofMDNCFReceptor.
￿
The saturability ofbinding of 1251-MDNCF
to neutrophils was examined. The total binding of MDNCF increased in propor-
tion to the amount of added labeled material. The specific binding was similarly
increased (Fig. 3) and was saturated in the presence of 25 ng 1251-MDNCF. The
nonspecific bindingofMDNCF increasedlinearly with increasingamountsofradio-
labeled ligand. The Scatchard analysis of specific MDNCF binding at 4°C after
3 h showed a curvilinear pattern. The equilibrium Kd was 8 x 10 -1° M, with the
number ofreceptors per neutrophil estimated to be "20,000%ell. This type of cur-
vature andnonlinear Scatchard plothas been obtained in many receptor-ligand in-
teractions (11). It was determined that the Hill coefficient (nH) was 1.09, indicating
no significant positive or negative cooperativityin bindingofMDNCF to receptors.
Therefore, the MDNCF receptors seem to have single binding affinity.
Chemical Crosslinking ofMDNCFwith Its Receptor.
￿
Chemical crosslinkingofMDNCF
with its receptor was carried out using a bivalent crosslinking reagent DSS. Fig. 4
presents autoradiographs ofSDS-PAGE with three different concentrations ofDSS
to fractionate thecell extracts under reducingconditions. Twobandsofmolwt 75,000
and 67,000 were detected. These signals disappeared in the presence ofexcess unla-
beled MDNCF, indicatingthatthe bandsrepresented MDNCFspecific binding mol-
ecules. Assuming that one MDNCF molecule binds to one receptor molecule, the
molecular weight of MDNCF binding proteins were estimated to be 67,000 and
oTotal binding
eSpecific binding
o Nonspecific binding
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FIGURE 2.
￿
Kinetics of 1251-MDNCF binding to human
neutrophils. 4 ng 1251-MDNCF (1.2 x 105 cpm) was in-
cubated with humanneutrophils at 4°C forindicated times.
Theresults representthree independent experiments. Each
point is the mean of duplicate determination.
FIGURE 3.
￿
Binding isotherm of 1251-MDNCF to human
PMN. Neutrophils were incubatedfor 3 hat 4°C with var-
ious concentrations of 1251-MDNCF, rangingfrom 0.39 to
24 nM. Nonspecific binding was determined in the pres-
ence ofexcess unlabeled(100-fold) MDNCF . To determine
specific binding, thenonspecific bindingwas subtracted from
the totalbinding. Shown in theinsetis the Scatchardanal-
ysis of thebindingdata. The resultsrepresentthree inde-
pendent experiments.1188
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FIGURE 4 . Autoradiograph of chemically crosslinked
MDNCF receptor complexes from human neutrophils ana-
lyzed by SDS-PAGE (10%) . Lanes 1, 3, and 5 present the
crosslinked molecules prepared in the absence ofunlabeled
MDNCFusing0.75, 1, and 1.25 mg/mlDSS, respectively.
Lanes 2, 4, and6 present the same experiment in the pres-
ence of an 80-fold excess of unlabeledMDNCF . The mo-
lecular weight markers of the standard proteins were also
run in SDS-PAGE as indicated in the figure . The results
represent three independent experiments .
59,000 . There was no significant difference in migration of the chemically cross-
linked receptors on SDS-PAGE under reducing and nonreducing conditions (data
not shown) . These two bands may represent noncovalently associated MDNCF
receptor subunits, proteolytically cleaved molecules, or posttranslationally modified
molecules as by glycosylation, acylation, and phosphorylation .
Increase ofMDNCF Receptor Expression on DMSO-treated HL60 Cells.
￿
The HL60
human promyelocytic leukemic cell line could be differentiated into myelocytes and
metamyelocytes by the addition of 1.25% DMSO (8) . The binding assay was first
carried out using a single saturating amount (4 ng) of 1251-MDNCF before and after
5 d of incubation withDMSO. In uninduced promyelocytes, the binding of the la-
beled material was low but was increased by fourfold in the DMSO-treated cells .
Scatchard analysis performed at 4°C showed that -7,000 receptors were present
per DMSO-treated HL60 cell . The Kd was 1 .2 x 10-9 M, which was similar to the
Kd value for the MDNCF receptors on normal peripheral blood neutrophils (data
not shown). This indicates that promyelocytes express small numbers ofMDNCF
receptors and that the expression ofthe MDNCF receptor increases with each suc-
cessive stage of maturation of neutrophils, becoming maximal in themature PMN.
In conclusion, we have reported the detection of an MDNCFspecific receptor
that is distinct from the receptors for other known chemoattractants . Purification
and further characterization of the MDNCF-specific receptor may provide insights
into the mechanism of action ofMDNCF .
Summary
Specific receptors forarecently purified and cloned monocyte-derived neutrophil
chemotactic factor(MDNCF) have been identified on thesurface of normal human
peripheral blood neutrophils using 125I-labeled recombinant human MDNCF (1251-
MDNCF) . Competitive binding of 1251-MDNCF to human neutrophils reached a
maximal level at 1-3 h at 4°C. The Scatchard analysis showed that there are "20,000SAMANTA ET AL.
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receptors per cell with a single type of high affinity binding (Kd, 8 x 10-t° M). The
receptors for MDNCF are clearly distinct from the receptors for other cytokines
and chemotactic agents, e.g., IL-la, TNFa, and FMLP, C5a, leukotriene B4, and
platelet activating factor. Based on the SDS-PAGE analysis of chemically crosslinked
1251-MDNCF receptor complex, there are two polypeptides that bind MDNCF; the
molecular weight of these two MDNCF receptors were estimated to be 67,000 and
59,000. Treatment of a promyelocytic cell line, HL60, with 1.25% DMSO for 5 d
in vitro increased the number of receptors up to 7,000 receptors/cell with a Kd of
1.2 x 10-9 M.
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